Navigation Links
When is a stem cell not really a stem cell?
Date:8/26/2007

Working with embryonic mouse brains, a team of Johns Hopkins scientists seems to have discovered an almost-too-easy way to distinguish between true neural stem cells and similar, but less potent versions. Their finding, reported this week in Nature, could simplify the isolation of stem cells not only from brain but also other body tissues.

What the researchers identified is a specific protein signal that appears to prevent neural stem cells the sort that might be used to rebuild a damaged nervous system from taking their first step toward becoming neurons. Stem cells dont instantly convert into functional adult tissue, says author Nicholas Gaiano, Ph.D., assistant professor at the Institute for Cell Engineering. They undergo a stepwise maturation where they gradually shed their stem cell properties.

The first step turns stem cells into progenitor cells by dictating how signals downstream of a protein called Notch, which regulates stem cells in many different tissues, are transmitted. One well known target of Notch is a protein called CBF1. To help study Notch signaling further, Gaiano and his team created genetically engineered mouse embryos that glow green when CBF1 is turned on.

To their surprise, they noticed that during brain development some of the brain cells generally thought to be neural stem cells stopped glowing, indicating that the CBF1 protein was no longer active in them. A closer look revealed that those cells that went dark were in fact no longer true neural stem cells, which can form all major brain cell types, but instead had aged into progenitor cells, which form mostly neurons.

They tested whether CBF1 was the critical switch by chemically knocking out the protein in neural stem cells. The knockout got the stem cells to rapidly convert to progenitor cells. However, if we activated the CBF1 protein in progenitor cells we couldnt get them to shift back into stem cells, says Gaiano. So whatever happens biochemically once CBF1 is turned off seems to create a one-way street.

Another recent study, using the mouse line generated by the Gaiano group, found that CBF1 signaling may play the same role in blood stem cells, leading Gaiano to suspect that his teams discovery might be a general switch distinguishing stem cells from progenitors in many different tissues.


'/>"/>

Contact: Nick Zagorski
nzagors1@jhmi.edu
443-287-2251
Johns Hopkins Medical Institutions
Source:Eurekalert

Related biology news :

1. Whats really making you sick? Plant pathologists offer the science behind Sick Building Syndrome
2. Researchers seek to discover what really happens when a virus enters the body
3. What does the public really know about HPV?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology: